BioCentury
ARTICLE | Company News

Angiogen, Microbix deal

April 10, 2006 7:00 AM UTC

MBX received exclusive worldwide rights to commercialize Angiogen's Angiostatic Cocktail, which is in Phase I testing for cancer. The product contains urokinase and an undisclosed small molecule. MBX ...